Docoh
Loading...

MRK Merck & Co

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Company profile

Ticker
MRK
Exchange
Website
CEO
Kenneth Frazier
Employees
Incorporated
Location
Fiscal year end
Former names
Merck & Co. Inc., SCHERING PLOUGH CORP
SEC CIK
IRS number
221918501

MRK stock data

(
)

Calendar

25 Feb 21
18 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Merck & Co earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 8.17B 8.17B 8.17B 8.17B 8.17B 8.17B
Cash burn (monthly) (positive/no burn) 147.42M 664.33M (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 531.56M 2.4B n/a n/a n/a
Cash remaining n/a 7.63B 5.77B n/a n/a n/a
Runway (months of cash) n/a 51.8 8.7 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Coe Mary Ellen Phantom Stock Common Stock Grant Aquire A No No 77.09 421.585 32.5K 8,337.186
31 Mar 21 Christine E Seidman Phantom Stock Common Stock Grant Aquire A No No 77.09 210.793 16.25K 3,509.551
31 Mar 21 Wendell Peter C Phantom Stock Common Stock Grant Aquire A No No 77.09 389.156 30K 100,545.25

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

73.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2522 2401 +5.0%
Opened positions 284 171 +66.1%
Closed positions 163 102 +59.8%
Increased positions 1132 1060 +6.8%
Reduced positions 833 878 -5.1%
13F shares
Current Prev Q Change
Total value 151.32B 153.33B -1.3%
Total shares 1.85B 1.84B +0.7%
Total puts 13.88M 12.69M +9.4%
Total calls 18.03M 17.52M +2.9%
Total put/call ratio 0.8 0.7 +6.3%
Largest owners
Shares Value Change
Vanguard 208.41M $17.05B -0.7%
BLK Blackrock 195.02M $15.95B -1.0%
STT State Street 114.15M $9.41B -2.5%
Geode Capital Management 42.1M $3.44B +1.8%
Wellington Management 40.66M $3.33B -9.1%
BAC Bank Of America 40.13M $3.28B -8.9%
Capital International Investors 34.65M $2.83B -9.3%
NTRS Northern Trust 32.87M $2.69B -2.6%
BK Bank Of New York Mellon 31.81M $2.6B -3.1%
BEN Franklin Resources 29.39M $2.4B +16.4%
Largest transactions
Shares Bought/sold Change
Norges Bank 27.52M +27.52M NEW
BRK.A Berkshire Hathaway 28.7M +6.29M +28.1%
Capital World Investors 20.43M -5.54M -21.3%
Epoch Investment Partners 0 -4.92M EXIT
FMR 7.62M -4.52M -37.2%
BEN Franklin Resources 29.39M +4.15M +16.4%
Nuveen Asset Management 24.25M +4.11M +20.4%
Wellington Management 40.66M -4.07M -9.1%
D. E. Shaw & Co. 9.92M +4.02M +68.2%
BAC Bank Of America 40.13M -3.91M -8.9%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Bad
New words: abiraterone, absent, acuminate, adjourned, advantage, advice, Ahead, AIN, alpha, anal, anogenital, anticompetitive, antiviral, Aon, Appendix, array, atherosclerotic, autoimmune, Aybintio, background, Bank, BARDA, baseline, belonging, belzutifan, Bio, Biomedical, biometric, Bioscience, bound, BRCAm, BRUN, burden, capecitabine, career, ccRCC, CECH, Centene, center, checkpoint, childcare, CHRISTINE, clear, colon, compensatory, concierge, concurrent, condyloma, conference, confident, consecutive, consent, contemporary, Council, counter, CRAIG, creatinine, culture, curative, curatively, CV, cyclosporine, dampening, Dean, debilitating, distancing, dMMR, dosage, duly, Dunboyne, easy, emotional, empowerment, England, enjoy, enzalutamide, epidemic, erected, ESCC, estrogen, ethnically, EUA, excel, excellence, exhibit, feedback, fifty, FIGO, Finland, Flavor, Fortune, foster, fostering, futility, GDPR, gemcitabine, gender, genetic, genetical, genital, Glasgow, glioblastoma, globe, GLOCER, graft, GU, Guaranty, harbor, hereto, Hewitt, hired, hiring, home, HRD, Humana, hygiene, IASLC, IAVI, IMPOWER, Indenture, inferior, INGE, injunction, Inline, inspire, interactive, interplay, intraepithelial, ipilimumab, ITT, Journal, JPN, KATHY, knowledge, Koselugo, ladiratuzumab, lag, LEAP, LESLIE, Li, licensure, Linkbase, lufenuron, MACE, Melinda, mental, MFN, microchip, Microspherix, milbemycin, Minnesota, molnupiravir, Morgan, Mother, motivate, Native, NCI, neoplasia, neurological, Nexplanon, nonfatal, nonmetastatic, nonprofit, notably, NR, NRDL, nutrition, ODAC, OECD, OIG, ointment, omitted, OncoImmune, onsite, ophthalmic, Optimmune, Organon, oropharyngeal, outpace, outreach, oxime, Padcev, PAMELA, pandemic, Pandion, papillary, Paragraph, parental, parity, Parliament, PATRICIA, PAUL, payor, Petcare, PETER, phosphate, pMMR, PN, posed, praziquantel, PRC, precision, premier, premium, PrEP, Presidentand, Presidential, proactive, processed, processing, proficient, pulse, quartile, Quebec, quickly, rank, ranking, ratified, recruiting, rectum, relebactum, representation, retention, revert, revocation, Ridgeback, RISA, ROTHMAN, Roughly, RUSSO, Salary, SAR, Schema, screening, Seagen, Seattle, SEIDMAN, Sentinel, serum, sex, shareable, sick, Silgard, simultaneously, situ, skill, spread, strict, stroke, struck, subgroup, successor, sued, supplier, systematically, Takeda, talent, talented, Taxonomy, TCA, team, temperature, temporarily, thereunto, threat, THULIN, thymic, today, topline, transgender, travel, triple, Trustee, tucatinib, Tukysa, UHC, unanimously, unchallenged, unconstitutional, undersigned, underway, unexplained, University, urgent, valuable, VelosBio, venue, Verquvo, VHL, Virbac, volunteer, volunteering, von, vulvar, WARDEN, Warranty, Week, wellbeing, WENDELL, whichever, wrongdoing, XBRL, Yervoy
Removed: aaa, accessing, Accountant, add, adding, advancement, Alto, Alzheimer, amend, amyloid, auto, backdrop, bacteremia, bench, carboplatin, card, certiorari, cleaving, cohort, comparative, compliant, complicated, composition, Condensed, conditional, constrain, constructive, differential, discharge, discrimination, discriminatory, disparate, distinct, earliest, Ebola, eDMC, enhanced, enzyme, ERISA, eroded, escrow, expedient, expressed, expressing, extinguishment, female, hostile, Hurricane, immunity, immunization, immunology, indemnification, induce, infect, innate, insuring, intensified, intratumoral, Intron, Kelli, kill, lamivudine, legacy, loan, lone, Maria, merger, Mine, modest, Moody, noncancellable, opposed, Palo, payer, pemetrexed, Perlmutter, pledged, Poor, potent, practical, preferentially, prodromal, producer, QIDP, qualifying, read, ready, redeem, repaid, repeal, replacement, replenished, resistant, retained, retaliation, retinoic, retrospective, Rigontec, Roger, secured, Shield, significance, spanning, stop, student, suffering, suppressed, tendered, tenofovir, thereto, threatening, tradename, Unresolved, uprifosbuvir, urinary, validly, Venezuela, verubecestat, writ